Micreos Pharmaceuticals Partners With Biologics CDMO Northway Biotech for Its Engineered Endolysin Therapeutic Manufacturing Program
Micreos is focused on developing best-in-class targeted therapeutics to precisely target harmful pathogens that cause disease flares to help address significant unmet medical needs in dermatology and oncology.
As part of the partnership, Northway Biotech will apply its significant expertise in biologics manufacturing to develop a scalable GMP production process for Micreos' engineered endolysin technology. The collaboration will also include developing and validating robust analytical methods, cell bank manufacturing, technology scale-up for cGMP Drug Substance generation, and IND/IMPD supporting documentation preparation, to ensure that the production of Micreos' engineered endolysins complies with stringent regulatory standards for clinical trials.
Matt Regan, CEO of Micreos, stated: "This partnership with Northway Biotech marks a significant milestone for Micreos as we advance our engineered endolysins into scalable therapeutics for clinical trials. By developing targeted medicines that address the underlying pathophysiology associated with disease aggravation in conditions such as atopic dermatitis and cutaneous T-Cell lymphoma, and by leveraging Northway's significant manufacturing expertise, we are poised to make a meaningful impact on patient care in areas of great unmet medical need."
Prof. Vladas Algirdas Bumelis, CEO and Chairman of Northway Biotech, highlighted the mutual commitment to high-quality manufacturing: "We are honored to contribute to Micreos' innovative engineered endolysin therapies. With a dedicated and highly experienced team in recombinant protein process development and scale-up, we aim to accelerate Micreos' development by providing cGMP drug substance material available by the end of summer 2024."
André Markmann, PhD, VP of Business Development at Northway Biotech, added: "Micreos' engineered endolysins address critical healthcare challenges. We are excited to support Micreos in advancing their breakthrough therapy into clinical trials at a rapid pace while ensuring the highest standards."
About MEndoB
Micreos' MEndoB is the first-in-class and potentially best-in-class dual-active domain, targeted medicine designed for optimum activity on human skin. It works through targeted enzymatic degradation of the targets cell wall, rapidly killing the harmful pathogen, but without triggering drug resistance or having any off target affects. Micreos' engineering expertise has enhanced drug stability and activity but has also been validated to effectively penetrate biofilms, eliminate dormant & hard to kill pathogenic cells, and potentially deliver synergies with other medications. With demonstrated preclinical efficacy, MEndoB holds significant promise for treating chronic and difficult-to-treat conditions in dermatology and oncology.
About Micreos
Micreos is a preclinical-stage biopharmaceutical company developing highly innovative, targeted therapies as a new way to treat chronic conditions in dermatology and oncology where there is a high unmet medical need. With its advanced engineering platform, Micreos is developing targeted medicines that selectively eliminate harmful pathogens while preserving the beneficial microbiome, paving the way for future indications in dermatology, oncology, and beyond.
For more information, visit www.micreos.com.
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced and professional team executes projects at every stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's extensive expertise and vertically integrated service offering enables rapid execution of multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development, and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and operates locations in Vilnius, Lithuania; London, United Kingdom; and Waltham, MA, USA.
For more information, please visit www.northwaybiotech.com.
Micreos Contact:
Matt ReganCEO and Board member, Micreos Pharmaceutical AGm.regan@micreos.com
Northway Biotech Contact:
Vladas Algirdas BumelisCEO and Chairman of the Boardvladas.bumelis@northwaybiotech.com
Contact Information
Vladas Bumelis CEO and Chairman of the Boardvladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 days ago
- Yahoo
Sharp Therapeutics Corp. Engages Rho Inc. to Help Advance Compounds into Clinical Trials for Gaucher Disease
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - July 29, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a preclinical-stage biotechnology company developing small molecule therapies to treat genetic diseases, today announced that it has engaged Rho, Inc. ("Rho"), a global contract research organization (CRO), to support Sharp's preparation and planned submission of its Investigational New Drug Application ("IND") to the U.S. Food and Drug Administration (the "FDA") for the evaluation of its clinical candidate compound ("'901") for the treatment of Gaucher disease. Gaucher disease is a genetic disorder caused by a deficiency in the enzyme glucocerebrosidase (also called beta-glucosidase or GBA1). Sharp's small molecule compound is a potential new orally available CNS-penetrant therapy for the treatment of Gaucher disease. "We are excited by the preclinical data from our Gaucher candidate, '901, and look forward to Rho's support in preparing our IND and other filings," said Scott Sneddon, PhD, JD and Chief Executive Officer of Sharp. "We intend to meet with FDA on our Phase I clinical plan, and to file for orphan drug designation this year. IND-enabling studies are also planned to commence before end of 2025. This is a key milestone for Sharp as we transition from a preclinical-stage to a clinical-stage company," he added. About '901 The '901 compound increases GBA1 activity for numerous mutations in Gaucher patient-derived cells, as well as increasing substrate turnover in a rodent model of Gaucher. Preclinical studies show the compound to be orally available and CNS-penetrant with good safety and preclinical pharmacology profiles. The compound is being targeted to all types of Gaucher with an application to GBA-associated Parkinson's disease also possible. The scientific data supporting the '901 series of compounds was presented at the GBA1 Conference in Montreal on June 5, 2025. That presentation is available on the Company's website at About Gaucher Disease Gaucher disease is a lysosomal storage disease caused by a deficiency in the GBA1 enzyme. Gaucher is the most common lysosomal storage disorder. Without this enzyme, the glucocerebroside lipid accumulates within the lysosomes of certain cells, particularly macrophages (immune cells). These overloaded cells, called "Gaucher cells," become enlarged and dysfunctional. The buildup primarily affects the spleen, liver, bone marrow, and sometimes the nervous system, leading to organ enlargement and the characteristic symptoms of the disease. This is the classic pattern of lysosomal storage diseases: enzyme deficiency → substrate accumulation → cellular dysfunction → organ pathology. About Rho, Inc. Rho is a global, privately held contract research organization (CRO) headquartered in Research Triangle Park, a biotech hub in North Carolina, US. Rho provides a full range of drug development services, from program strategy through to clinical trials and marketing applications. Since 1984, Rho has been a trusted partner to some of the most innovative pharmaceutical, biotechnology and medical device companies as well as academic and government organizations. Dedicated to service excellence and cross-functional collaboration, Rho's therapeutic expertise, employee focus and commitment to strong site relationships change what it means to work with a CRO – accelerating time to market, maximizing ROI, and delivering consistent, smarter and more efficient programs. Experience Rho by following the company on LinkedIn. About Sharp Therapeutics Corp. - First-Choice Therapies for Genetic Diseases Sharp Therapeutics is a preclinical-stage company developing small-molecule therapeutics for genetic diseases. The Company's discovery platform combines novel high throughput screening technologies, with compound libraries computational optimized based on the physics and biology of cellular trafficking defects and allosteric activation of proteins. The platform produces small molecule compounds that restore activity in mutated proteins giving the potential to treat genetic disorders with conventional pill-based medicines. For additional information on Sharp, please visit: Sharp Therapeutics Sneddon, PhD, JDCEO/CSOEmail: scott@ Caution Regarding Forward-Looking Information Certain statements contained in this press release constitute "forward-looking information" as such term is defined in applicable Canadian securities legislation. The words "may", "would", "could", "should", "potential", "will", "seek", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect Sharp's current views and intentions with respect to future events, and current information available to Sharp, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. Should any factor affect Sharp in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, Sharp does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and Sharp undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
San Francisco Chronicle
7 days ago
- San Francisco Chronicle
The Bay Area suburbs where renters are taking over the market
For decades, the path from renter to homeowner in America looked like this: You rent in a big city when you're just starting out, then once you've settled into your career and personal life, you buy a house in the suburbs. But high home prices combined with 30-year mortgage rates stubbornly stuck in the sixes have kept home ownership out of reach for many for the past few years, especially in the Bay Area. A new study from Point2Homes shows that renter households now outnumber homeowners in more than 200 metropolitan suburbs nationwide. Point2Homes provided the Chronicle with data on the share of renters in the smaller cities around the San Francisco, Oakland and Fremont metropolitan area (the data excludes San Jose and most of the South Bay, which are considered a separate metro). In 24 of the 54 cities analyzed, the percentage of the population that rents is rising. In seven of them, renters now represent larger shares of the population than homeowners. The trend is accelerating at an even faster rate on the East Coast, said Doug Ressler, the manager of business intelligence for data acquisition firm Yardi Matrix, who worked on the data cited in the Points2Homes study. Both companies are owned by Santa Barbara-based real estate software company Yardi Systems. In 15 metropolitan areas, suburban cities transitioned from majority-owner to majority-renter between 2018 and 2023; in another 15, the number of renter households more than doubled. In the Dallas, Minneapolis, Boston, Tampa and Baltimore areas, the suburbs gained renters faster than the big cities they surround. But that's not quite what's happening in the Bay Area. All the cities that are renter-majority as of 2023 in the San Francisco area were already that way in 2018. Of the 54 cities analyzed, the share of renters dropped in 30 of them, though in some of them not by a statistically significant amount. Taken together, the 54 cities experienced a modest net 1.9% increase in renter household growth during that period. The reason we're not seeing the same explosion in renting that some cities on the East Coast are is the same as the explanation for many of the Bay Area's problems: It's hard to build housing here. 'We don't build enough housing compared to the wealth and jobs we create,' said Matt Regan, senior vice president of policy for the Bay Area Council, a pro-housing advocacy group. The urban cores themselves 'make it ridiculously hard to build,' he said, which leads developers to look for opportunities in suburbs and exurbs. But even in smaller cities and suburban areas, Regan said, many local governments have determined that the right place to build more homes and apartments is 'somewhere else.' 'The Bay Area has been ground zero for 'not in my backyard,'' said Jeff Ostrowski, a housing market analyst for Bankrate. A combination of growth restrictions, lack of land and income growth have created what he called the 'perfect storm for an explosion of property prices.' As housing prices have risen, the age of the average first-time homebuyer in the U.S. has increased, meaning people are renting for longer. The median first-time homebuyer is now 38 years old, according to the National Association of Realtors. The years 2018 to 2023 are an interesting period for studying housing trends in America. The COVID-19 pandemic created a drastic shift: Rents rose, mortgage rates hit rock bottom, and remote work vaporized commutes. California's population declined by more than half a million people from April 2020 to July 2022, though it's bounced back since then. COVID played a dual role: Some people left because a fully remote job meant they could live somewhere more affordable. And the polarization of pandemic restrictions and vaccine policies drove some people to search for alternative political climates. Some workers who were given free rein to move to Texas or Idaho found themselves recalled by return-to-office policies. But even now, many offices in the Bay Area have only partial RTO: Office visits are down 44.6% in San Francisco this year compared with 2019, according to a study from location data analysis firm That makes the suburbs a more appealing place to live, Regan said. Only needing to drive to the office two or three days a week instead of five makes an onerous commute slightly less daunting. So there's interest in more housing in the suburbs — but challenges to build it. Regan said California's condo defect liability laws dissuade developers from building a type of housing that was traditionally a solid first rung on the property ladder. Many cities are out of space to build single-family homes. That leaves apartment buildings, which can be appealing to developers given the region's high incomes and high demand, but often face planning and permitting issues and anti-renter sentiment from homeowners. A standout on the list of cities with a high renter share is Emeryville. The share of renters increased by 28% from 2018 to 2023, with the city adding more than 1,100 renter households. Cities that have seen more renter growth tend to have certain things in common, said Ressler of Point2Homes. They're usually situated close to transit; have social amenities such as parks, community centers and museums; have less expensive land compared with the urban areas; and have local governments that are amenable to housing development. Regan said Emeryville's government has embraced housing growth alongside job growth from companies such as Pixar and commercial growth from major retailers including IKEA. Emeryville has 'been willing to accept that with economic growth comes a demand for housing, and they have built a commensurate amount of new housing units to accommodate their economic growth,' Regan said. 'Most cities in our region are happy to take the jobs and then increase their tax base, but have traditionally not been willing to build the housing.'
Yahoo
25-07-2025
- Yahoo
Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million
The combined company will operate under the name 'ImageneBio, Inc.' and will begin trading on Nasdaq under the ticker symbol 'IMA' at market open on Monday, July 28, 2025 ImageneBio, Inc. will continue to drive the ongoing Phase 2b clinical trial of non-depleting anti-OX40 monoclonal antibody, IMG-007, in patients with moderate-to-severe atopic dermatitis Phase 2b topline readout for IMG-007 in atopic dermatitis expected in the fourth quarter of 2026 SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals ('Inmagene'), a clinical stage biotechnology company dedicated to developing disease-modifying treatments for immunological/autoimmune and inflammatory ('I&I') diseases, today announced the completion of its previously announced merger with Ikena Oncology, Inc. (Nasdaq: IKNA) ('Ikena'). The combined company will operate under the name ImageneBio, Inc. ('ImageneBio') and will trade on The Nasdaq Capital Market ('Nasdaq') under the ticker symbol 'IMA' beginning at market open on July 28, 2025. Concurrent with the closing of the merger, Inmagene and Ikena completed a $75.0 million private placement with a syndicate of existing and new investors including Deep Track Capital, Foresite Capital, RTW Investments, and existing Ikena investors such as BVF Partners L.P., Blue Owl Healthcare Opportunities, Omega Funds, and OrbiMed. The combined company will be led by Kristin Yarema, Ph.D. as its Chief Executive Officer, as announced earlier this week. 'We are pleased with the outcome of this transaction and are well-positioned to advance IMG-007 into late-stage development. OX40 inhibition is a promising approach that may have the potential to treat a broad range of immunological and inflammatory diseases where patients continue to wait for more and novel treatment options. We are excited about the emerging profile of IMG-007, which we believe will prove to be differentiated, and we look forward to executing our development plan in atopic dermatitis and potentially initiating studies in additional indications,' commented Dr. Kristin Yarema. Additionally, in connection with the completion of the transaction and as recently approved by Ikena's shareholders, Ikena implemented a reverse split of its common stock at a ratio of 1-for-12 shares. Following the reverse stock split and based on the final exchange ratio of approximately 0.003051 shares of Ikena common stock for each Inmagene share, immediately following the closing of the merger, the legacy equity holders of Inmagene owned approximately 55.0% of the combined company's outstanding common stock and the legacy equity holders of Ikena owned approximately 45.0% of the combined company's outstanding common stock, in each case, on a fully diluted basis. Following the consummation of the concurrent private placement, the legacy equity holders of Inmagene owned approximately 43.1% of the combined company's outstanding common stock, the legacy equity holders of Ikena owned approximately 35.3% of the combined company's outstanding common stock, and the investors in the concurrent financing owned approximately 21.6% of the combined company's outstanding common stock, in each case, on a fully diluted basis. Following the reverse stock split, the closing of both the merger and concurrent financing, ImageneBio will have approximately 11.6 million shares of common stock outstanding. ImageneBio's shares are expected to begin trading on Nasdaq at market open on July 28, 2025 under the ticker symbol 'IMA' and new CUSIP number, 45175G 207. AdvisorsGoodwin Procter LLP served as legal counsel to Ikena, and Cooley LLP served as legal counsel to Inmagene. Leerink Partners LLC served as exclusive financial advisor to Ikena. Evercore served as exclusive financial advisor to Inmagene. About ImageneBio, Inc. ImageneBio is a clinical-stage biotechnology company that boldly imagines a world where patients can be free from the burden of grievous immunological/autoimmune and inflammatory ('I&I') diseases. Imagene's purpose is to globally develop new medicines with differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The company's lead asset IMG-007, a nondepleting anti-OX40 monoclonal antibody, recently completed Phase 2a clinical trials in atopic dermatitis and alopecia areata. ImageneBio is currently conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis. For more information, please visit About IMG-007 IMG-007 is an investigational, non-depleting monoclonal antibody targeting OX40, a receptor protein primarily found on activated human T cells. When OX40 binds its ligand OX40L in human tissue, the signal generated plays a key role in the activation, expansion, and survival for many subtypes of T cells. Targeted inhibition of OX40 is thus an emerging potential therapeutic strategy to treat a wide range of I&I diseases where aberrant signaling of one or more T cell subtypes is believed to drive disease. IMG-007 has been engineered to include a silenced antibody-dependent cell-mediated cytotoxicity function to avoid T cell depletion or killing, to minimize safety risk. This technology also resulted in extended half-life to prolong therapeutic activity with the aim of maximizing time between doses for a patient. In Phase 2a trials in patients with moderate-to-severe atopic dermatitis and severe alopecia areata, IMG-007 exhibited sustained clinical and pharmacodynamic activity and was well tolerated. IMG-007 was originally discovered by HUTCHMED. Clinical development is ongoing: additional information about the ongoing Phase 2b trial in moderate-to-severe atopic dermatitis is available at using identifier: NCT07037901. Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, express or implied statements regarding the anticipated benefits of the merger; the expected trading of the combined company's stock on Nasdaq under the ticker symbol 'IMA' and on a post-reverse stock split basis; the future operations of the combined company; the nature, strategy and focus of the combined company; the development and commercial potential and potential value and benefits of IMG-007; planned or anticipated preclinical and clinical drug development activities and related timelines, including the expected timing for data and other clinical results and the potential initiation of studies in additional indications; the expected leadership of the combined company; the potential to receive and distribute any proceeds pursuant to the contingent value rights agreement of Ikena and contingent value rights agreement of Inmagene; and other statements regarding management's intentions, plans, beliefs, expectations or forecasts for the future. All statements other than statements of historical fact contained in this press release are forward-looking statements. These forward-looking statements are made as of the date they were first issued, and were based on the then-current expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management of each of Inmagene and Ikena. There can be no assurance that future developments affecting the combined company or any future transactions or distributions described herein will be those that have been anticipated. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond ImageneBio's control. ImageneBio's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: risks associated with the possible failure to realize certain anticipated benefits of the merger, including with respect to future financial and operating results; potential litigation relating to the transaction that could be instituted against the combined company or its directors; risks related to the commencement of shares to begin trading on Nasdaq; the uncertainties associated with the combined company's current and future product candidates, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the completion of clinical trials and potential safety and other complications thereof; the significant net losses that the combined company has incurred since inception; the combined company's ability to initiate and complete ongoing and planned preclinical studies and clinical trials and advance its product candidates through clinical development; the timing of the availability of data from the combined company's clinical trials; the outcome of preclinical testing and clinical trials of the combined company's product candidates, including the ability of those trials to satisfy relevant governmental or regulatory requirements; pre-clinical and clinical results may not be indicative of results that may be observed in the future; the combined company's plans to research, develop and commercialize IMG-007 or its future product candidates; the clinical utility, potential benefits and market acceptance of the combined company's product candidates; the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all; the combined company's ability to attract, hire, and retain skilled executive officers and employees; the combined company's ability to protect its intellectual property and proprietary technologies; the combined company's reliance on third parties, contract manufacturers, and contract research organizations; the possibility that the combined company may be adversely affected by other economic, political, business, or competitive factors; risks associated with changes in applicable laws or regulations or government resources and policies; and the possibility that contingent value rights holders of legacy Ikena and contingent value rights holders of legacy Inmagene may never receive any proceeds pursuant to the Ikena contingent value rights agreement and Inmagene contingent value rights agreement. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. These and other risks and uncertainties are more fully described in Ikena's periodic filings with the Securities and Exchange Commission (the 'SEC'), including the factors described in the section titled 'Risk Factors' in Ikena's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the SEC on July 24, 2025, as well as the Form S-4, as amended (File No. 333- 285881), initially filed by Ikena with the SEC on March 18, 2025, and declared effective on June 11, 2025 and other documents subsequently filed with or furnished by the combined company to the SEC. You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or as of the dates indicated in the forward-looking statements. Except as may be required under applicable law, ImageneBio expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. This press release does not purport to summarize all of the conditions, risks and other attributes of an investment in the combined company. ImageneBio Contact:Anna Vardanyanvardanyana@ Brian Ritchie britchie@
